Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-term benefit to the majority of patients with cancer. Understanding genomic correlates of response and resistance to checkpoint blockade may enhance benefits for patients with cancer by elucidating biomarkers for patient stratification and resistance mechanisms for therapeutic targeting. Here we review emerging genomic markers of checkpoint blockade response, including those related to neoantigens, antigen presentation, DNA repair, and oncogenic pathways. Compelling evidence also points to a role for T cell functionality, checkpoint regulators, chromatin modifiers, and copy-number alterations in mediating selective response to immune checkpoint blockade. Ultimately, efforts to contextualize genomic correlates of response into the larger understanding of tumor immune biology will build a foundation for the development of novel biomarkers and therapies to overcome resistance to checkpoint blockade.
T umors have long been known to generate varying levels of immune response, a property termed immunogenicity. Early studies revealed that certain cancers maintained high levels of tumor-infiltrating lymphocytes (TILs), associated with improved prognosis 1, 2 . TILs have been shown to be dysfunctional and to express multiple co-inhibitory or checkpoint receptors, such as cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152), programmed cell death-1 (PD-1, CD279), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), and lymphocyte-activation gene (LAG-3) [3] [4] [5] . The insight that blockade of these checkpoints can lead to reversal of TIL dysfunction with improved cytotoxicity and proliferative capacity of these cells has changed cancer treatment paradigms (Box 1). Immune checkpoint inhibitors, including monoclonal antibodies against PD-1 and CTLA-4, have generated durable responses across many tumor types [6] [7] [8] [9] [10] [11] [12] [13] , leading to a number of Food and Drug Administration (FDA)-approved agents, with many others in the clinical trial pipeline. However, the majority of patients do not respond to checkpoint blockade, so predicting among patients the subset that will benefit from checkpoint inhibitors, either alone or in combination with other agents, remains a challenge.
Select tumors express high levels of the PD-1-binding ligand PD-L1, and initial trials of anti-PD-1 therapy found that PD-L1 expression, as detected by immunohistochemistry, correlated with response to therapy 6, 7, 14 , thereby leading the FDA to approve PD-L1 companion diagnostic tests for anti-PD-1/PD-L1 therapies in some cancers 15 . Additional studies of these histological markers showed that the association with response varied over time and by tumor type, with PD-L1 positivity distinguishing responders in some settings and not others 12, [16] [17] [18] . Importantly, subsequent trials have demonstrated that a sizable portion of responses occurred in patients with PD-L1-negative tumors 8, 11, [19] [20] [21] . These findings have prompted efforts to identify other determinants of response to checkpoint blockade, including non-genomic factors, such as the gut microbiome, environmental influences, and metabolic pathways, reviewed elsewhere [22] [23] [24] [25] [26] . Pivotal investigations of the cancer genome have uncovered oncogenic mutations underlying selective growth advantage, tumor suppressor inactivation, and tumorigenesis initiation, among others [27] [28] [29] . While such approaches have traditionally focused on genomic changes within tumor cells alone as a measure of responsiveness to small-molecule inhibitors or monoclonal antibodies, application of these strategies to immune checkpoint blockade requires consideration of tumor cells in conjunction with distinct immune cell populations and non-immune, non-tumor cells, such as stromal and endothelial cells. In this Review, we present a framework for emerging genomic correlates of clinical responses to immune checkpoint inhibitors ( Fig. 1 and Table 1) , discuss potential therapeutic applications of these findings, and outline crucial future studies needed to advance this field.
Tumor antigens and mutations
In order to avoid self-reactivity and the development of autoimmunity, the immune system discriminates self from non-self antigens. Tumors may express aberrant antigens that, in turn, may be recog nized by the immune system. These include proteins normally expressed in immune-privileged sites, such as cancer/testis antigens; virally expressed proteins, as in the case of Epstein-Barr virus or human-papillomavirus-associated cancers; and proteins encoded by endogenous retroviruses, which are germline genomic elements resembling retroviruses that are transcriptionally repressed in normal cells but expressed in many tumor cells [30] [31] [32] . Furthermore, tumors contain the cumulative sum of thousands of mutations, a fraction of which alter the amino acid sequence of encoded proteins. These mutated proteins, unique to the tumor and not present in normal cells, are known as neoantigens 25, 30 . Neoantigens are often specific to each tumor and are unlikely to be shared widely across tumors, even those with the same histology. If neoantigen epitopes are presented to the immune system, these epitopes generate an adaptive immune response selective for cancer cells that can be enhanced and strengthened by checkpoint blockade 30, 33 .
Neoantigens and tumor mutational burden.
A diversity of neoantigens may be necessary but not sufficient for clinical responses to immune checkpoint inhibitors. Mouse models of sarcoma that respond to anti-CTLA-4 and/or anti-PD-1 therapy have shown reactivation of neoantigen-specific T cells (Box 1) 34, 35 , and neoantigen-specific T cell reactivity has also been observed through tumor exome analysis in patients with advanced cancers who respond to checkpoint inhibitors 36, 37 . The role of neoantigens in the response to immune checkpoint inhibitors has been further substantiated
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by studies showing that higher neoantigen load is associated with response to CTLA-4 and PD-1 blockade in patients with melanoma and non-small-cell lung cancer [38] [39] [40] , as well as analyses of acquired resistance in patients with non-small-cell lung cancer demonstrating loss of neoantigens through subclone elimination and chromosomal deletions in resistant tumors 41 .
As neoantigens are computationally predicted from somatic variant data, tumor mutational burden, measured as the number of nonsynonymous mutations per megabase sequenced, has therefore similarly been associated with improved responses to checkpoint blockade, initially in studies of melanoma and non-small-cell lung cancer, two of the tumor types with the highest mutation number 38, 39, 42 . Larger studies and phase III trials have confirmed that high tumor mutational burden correlates with enhanced checkpoint inhibitor responses and improved overall survival in certain tumor types, such as head and neck cancer 43 , urothelial carcinoma 9 , and lung cancer [44] [45] [46] [47] [48] , including small-cell lung cancer 48 . However, tumor mutational burden is an incomplete correlate of checkpoint blockade response in that mutation load distributions overlap considerably between responders and nonresponders 38, 39, 42 . Therefore, even the most ideal receiver operating charcteristic curve cutoffs for tumor mutational burden in melanoma and lung cancer have low statistical sensitivity and specificity for predicting clinical benefit from checkpoint inhibitors 49 . Furthermore, tumor mutational burden does not correlate with response in other tumor types, including Hodgkin's lymphoma 50, 51 , renal cell carcinoma 52, 53 , and virally mediated tumors, such as polyomavirus-associated Merkel-cell carcinoma [54] [55] [56] , for which other factors likely drive responses to immune checkpoint inhibitors.
While a higher mutation and neoantigen load may reflect an increased likelihood of a T cell response being generated against that tumor, this has not necessarily correlated with the identification of circulating T cells that recognize the proposed neoepitope.
Mouse models of sarcoma have demonstrated that anti-CTLA-4 and anti-PD-1 therapies reactivated neoantigen-specific CD8 + T cells to achieve tumor rejection 34, 35 , and patients with cancers that responded to checkpoint inhibitors displayed neoantigen-specific T cell reactivity 36, 37, 57 . In both settings, the number of identified neoantigen-specific T cells was much lower than the predicted number of neo-epitopes. Whether this reflects underlying thymic deletion of tumor-reactive T cells with partial self-reactivity or a lack of sensitivity to identify the neoantigen-specific T cell population remains to be understood.
Neoantigen prediction. Refining neoantigen prediction algorithms for neoepitopes may improve the ability to identify patients who are most likely to respond to checkpoint blockade. Initial techniques to identify the peptide sequences most likely to be presented by major histocompatibility complex (MHC) class I proteins relied on in silico binding assays followed by in vitro testing with T cell clones 58, 59 . Subsequent efforts that were focused on large-scale mass-spectrometry approaches have led to the development of more advanced prediction algorithms 60, 61 . Similar efforts to identify class II neoepitopes have lagged behind due to, at least in part, the longer amino acid sequences and less stringent binding affinity rules required for class II binding 62 . Recently, methods to detect class II epitopes have been developed using neural network analysis of data derived from proteomic experiments and single-cell T cell receptor (TCR) sequencing 63 . Improved prediction algo rithms for both class I and II epitopes may enable a precision-medicine approach for neoantigen prioritization to be tested at an individualpatient level.
Neoantigen and mutation clonality. The relative clonality of neoantigens and mutations, estimated by the portion of tumor cells harboring a mutation, has also been linked to response. In one study, clonal neoantigens, arising from founder mutations present in all or nearly all tumor cells, conferred sensitivity to PD-1 and CTLA-4 blockade in lung cancer and melanoma, while subclonal neoantigens, which arise from passenger mutations present in a subset of tumor cells, predominated in non-responders 57 . Similarly, clonal neoantigens and mutations occurred recurrently in responding tumors in a meta-analysis of 249 tumors, predominantly melanoma and non-small-cell lung cancer, that were treated with immune checkpoint blockade 53 . This correlation between neoantigen clonality and checkpoint blockade response may be explained by immunoediting, in which immunogenic neoantigens trigger an antitumor immune response that then eliminates these neoantigens 64 . This phenomenon may thus restrict intratumor genetic heterogeneity
Box 1 | Tumor immunogenicity
The foundation of anti-tumor immunity rests on the generation or reactivation of cytotoxic T cell responses. T cell activation is a highly coordinated and regulated activity, requiring initial stimulation through both the T cell receptor (TCR) and co-stimulatory molecules, such as CD28, a protein expressed on T cells that interacts with the ligands B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells. CTLA-4 competitively binds with high affinity to these ligands to limit initial co-stimulatory signals in lymph nodes 184 . Although murine models initially suggested that anti-CTLA-4 therapy also depleted regulatory T cells [185] [186] [187] , which constitutively express CTLA-4, recent human studies have shown conflicting results 188, 189 . PD-1, in comparison, is induced following initial T cell activation to regulate T cells 190 . PD-1 binds the ligands PD-L1 and PD-L2 to attenuate TCR signaling 191 , thereby leading to decreased T cell proliferation, cytotoxicity, and cytokine production 192 . . Neoantigen clonality may therefore identify tumors with less sophisticated immune evasion strategies than those of nonresponding tumors. Overall, neoantigen clonality needs additional validation before it can be used as a clinical biomarker.
Neoantigen
Tumor immune evasion pathways
Tumor antigen immunogenicity. Furthermore, the similarity of neoantigens and other tumor antigens to non-self antigens, such as those expressed by viruses and other pathogens, may enhance immune recognition and checkpoint blockade response. Recent efforts have focused on quantifying the foreignness of neoantigens by comparing the neoantigen peptide sequences with those of immune epitopes that have been experimentally validated as targets of adaptive immune responses 65, 66 . In one neoantigen fitness model, tumors with more immunogenic neoantigens, which had greater homology with infectious-disease-derived peptides, were defined as having lower fitness 65, 66 . Patients with low-fitness melanoma and lung cancer tumors had longer survival after CTLA-4 and PD-1 blockade than patients with high-fitness tumors 65 . A similar concept may explain the improved responses to checkpoint blockade that were observed in virus-associated cancers, which have more immunogenic non-self antigens 31, 54 . Likewise, tumors with aberrant expression of germline endogenous retroviruses, which are transcriptionally repressed in normal cells, have demonstrated greater immune cytolytic activity and more frequent responses to checkpoint blockade 32, 67 . Altogether, the foreignness of tumor antigens may prove to be a stronger driver of checkpoint inhibitor response than the quantity of neoantigens.
Cancer/testis antigens. Cancer/testis antigens, whose normal expression is restricted to developing reproductive tissues 30, 33 , represent an alternative class of tumor antigens in that they consist of nonmutated self peptides that induce incomplete T cell tolerance and thus promote tumor immune evasion. Cancer/testis antigens are commonly expressed in many tumor types and have recently been implicated in resistance to immune checkpoint blockade. In metastatic melanoma, anti-CTLA-4 non-responders, but not anti-PD-1 non-responders harbored upregulated gene expression of a subcluster of melanoma-associated antigen (MAGE)-A cancergermline antigens 68 . Notably, MAGE-A protein expression correlated with decreased expression of autophagy proteins, indicating that MAGE-A proteins may suppress autophagy to prevent T cell priming and avert immune recognition 68 . Whether other cancer/ testis antigens similarly trigger immune tolerance and checkpoint blockade resistance remains to be determined.
Antigen presentation
HLA pathway alterations. Anti-tumor immunity requires T cell recognition of the tumor epitope when presented on the MHC, a process known as antigen presentation. Human leukocyte antigen (HLA) genes HLA-A, HLA-B, and HLA-C encode the MHC class I proteins that present intracellular peptides on the cell surface to TCRs and require β-2 microglobulin (B2M) for stabilization on the cell surface (Fig. 2a) 
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. While B2M loss was initially observed in tumor immune escape after adoptive T cell therapies 70 , B2M mutations and loss of heterozygosity have more recently been demonstrated to be innate and acquired resistance mechanisms to CTLA-4 and PD-1 inhibitors in cohorts of patients with melanoma 71 , as well Ranging from 0 to 1, with 1 indicating a monoclonal population Greater stemness 147, 150 Express chemokine receptor CXCR5 and transcription factor TCF7; lack TIM-3/CD39
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Mutational signatures 39, 53, 108 Smoking, ultraviolet light, alkylating agent therapy, APOBEC . These clinical observations are backed by preclinical experiments in which CRISPR-mediated knockout of B2m conferred resistance to PD-1 blockade in mouse models [73] [74] [75] [76] . The heterogeneity of alterations in B2M and tumor types in which they are found suggest that this mechanism of resistance may prove to be more widespread as more studies are performed.
Similarly, mutations within HLA genes, loss of diversity of HLA alleles, or alterations in HLA expression may diminish responses to checkpoint blockade. The extreme polymorphism of HLA genes has led to the concept that broader HLA diversity confers a survival advantage by promoting recognition by T cells of larger numbers of microbial and tumor antigens 77, 78 . An individual's HLA repertoire may exert a negative selection pressure on tumor mutations in that patient-specific MHC I and MHC II genotypes correlate with tumor mutations that produce neoantigens least likely to be presented, thus indicating immune evasion 79, 80 . Likewise, the presence of HLA mutations directly correlated with neoantigen frequency and TIL quantity in colorectal tumors, suggesting that positive selection was occurring for HLA mutations in tumors under immune attack 81 . HLA loss of heterozygosity was similarly associated with a high burden of subclonal neoantigens that were predicted to bind to the lost HLA alleles, implying that there was enhanced immune evasion after the loss of heterozygosity event 57 .
In the clinic, broader HLA diversity enhanced immune recognition of tumor neoantigens and improved overall survival in individuals with cancer treated with immune checkpoint inhibitors 82 . Similarly, higher expression of MEX3B, a gene encoding an RNAbinding protein that downregulates HLA-A expression (Fig. 2a) , was associated with primary resistance to anti-PD-1 therapy in melanoma 83 . Finally, in patients with melanoma who were treated with immune checkpoint inhibitors, loss of MHC class I protein expression on tumor cells correlated with transcriptional downregulation of HLA-A, HLA-B, HLA-C, and B2M and primary resistance to anti-CTLA-4 therapy, while MHC class II protein expression predicted response to anti-PD-1 therapy, again highlighting the importance of HLA expression in checkpoint blockade response 84 .
Interferon-γ pathway alterations. Expression levels of HLA molecules and response to checkpoint blockade may in part be driven by signaling through the interferon (IFN)-γ receptor. As shown in Fig. 2b , IFN-γ, released by activated T cells upon recognizing neoantigens, binds IFN-γ receptors on tumors, which triggers Janus kinase 1 (JAK1) 1 and JAK2 and signal transducers and activators of transcription (STAT) signaling that activates IFN-related genes, including interferon regulatory factor 1 (IRF1), which induces the transcription of other genes to increase the surface expression of PD-L1 and MHC molecules. Gene expression from 220 anti-PD-1-treated patients with nine cancer types revealed a T-cell-inflamed signature that included upregulated IFN-γ response that was necessary but not always sufficient for clinical benefit from therapy 85 . Similarly, enriched expression of genes related to antigen presentation and the IFN-γ pathway was an early on-treatment signature of melanoma tumor response to anti-PD-1 therapy after prior progression on anti-CTLA-4 therapy 86 . In addition to overall expression, copy-number alterations (CNAs) and mutations within the IFN-γ pathway have been identified as a mechanism of checkpoint inhibitor resistance. Of 12 melanoma tumors with primary resistance to anti-CTLA-4 therapy, 75% harbored genomic defects in the IFN-γ pathway, including copynumber loss of interferon-γ receptor 1 (IFNGR1), IFNGR2, IRF1, and JAK2, as well as amplification of IFN-γ pathway inhibitors, such as suppressor of cytokine signaling 1 (SOCS1) and protein inhibitor of activated STAT4 (PIAS4) (Fig. 2b ) 87 . Likewise, significant enrichment of IFN-γ CNAs occurred in non-responding compared with responding tumors in a meta-analysis of 249 checkpoint-inhibitor-treated tumors 53 . Collectively, these results highlight the importance of antigen presentation and IFN-γ pathway genes in response to immune checkpoint blockade.
Mutations in the JAK-STAT pathway have similarly been identified in primary and acquired resistance to immune checkpoint inhibitors, albeit at a lower frequency than IFN-γ expression changes. JAK1 or JAK2 mutations have been reported in small numbers of patients with metastatic melanoma and MMR-deficient colon cancer that demonstrated primary or acquired resistance to anti-PD-1 therapy 72, 88, 89 . Although JAK1 and JAK2 are canonically thought to act downstream of the IFN-γ receptor, other JAK-STAT pathway components may be involved in PD-L1 induction, as demonstrated by genomic profiling of a lung adenocarcinoma tumor responding to anti-PD-L1 therapy, which revealed activating germline and somatic JAK3 mutations that were associated with increased PD-L1 expression in response to IFN-γ (ref. 90 ). These clinical observations prompted preclinical CRISPR-Cas9 screens that aimed to identify regulators of the IFN-γ pathway [74] [75] [76] , which require validation in patients. These findings suggest that the full spectrum of factors mediating IFN-γ resistance is not fully understood and highlight this as an area to investigate for therapeutic targets to boost checkpoint blockade response. , loss of protein tyrosine phosphatase non-receptor type 2 (PTPN2) 74 , and germline HLA heterozygosity 82 . Conversely, genomic pathways of resistance include B2M loss 37, [71] [72] [73] , somatic HLA loss of heterozygosity 82 , reduced HLA gene expression 84 , increased expression of MEX3B 83 , IFNGR1/2 or IRF1 copynumber loss 87 , JAK1/2 inactivation 72, 88, 89 , APLNR (apelin receptor) loss 76 , and amplification of negative regulators of the IFN-γ pathway, including SOCS1 (suppressor of cytokine signaling 1) and PIAS4 (protein inhibitor of activated STAT4) 87 . Credit: Debbie Maizels/Springer Nature . Augmented JAK-STAT signaling and PD-L1 overexpression may contribute to impressive anti-PD-1 response rates of 69-87% in relapsed or refractory classic Hodgkin's lymphoma 50, 92, 93 . PD-L1 overexpression has also been correlated with CNAs in 9p24.1 in primary central nervous system B cell lymphoma and primary testicular B cell lymphoma, with corresponding high responses to anti-PD-1 therapy 94 . Conversely, PD-L1 overexpression in T cell non-Hodgkin lymphoma has been linked to poor outcomes-specifically, rapid progression in three patients with adult T cell leukemia-lymphoma treated with PD-1 inhibitors 95 . These clinical observations may be explained by the role of PD-1 as a tumor suppressor in T cell lymphomas and particularly by the ability of PD-1 to block oncogenic TCR signaling 96 . Overall, these findings caution against employing PD-1 blockade in tumors driven by oncogenic T cell signaling.
The frequency of PDL1 amplification in solid tumors, in comparison, is reported to be much lower, with a prevalence of 0.7% in over 118,000 sequenced tumors, inclusive of 100 solid tumor histologic types 97 . Enrichment was seen in particular tumor types, including hepatocellular cholangiocarcinoma, head and neck squamous cell, nasopharyngeal carcinoma, undifferentiated soft-tissue sarcoma, kidney sarcomatoid, and thyroid anaplastic carcinoma, of which 12 of 13 patients with clinical annotation had co-amplification of JAK2 (ref. 97 ). PDL1-amplified tumors did not always have high PD-L1 expression as determined by immunohistochemistry, echoing an earlier report in head and neck squamous cell tumors 96 . Within a clinically annotated cohort, 9 of 13 patients with identified PDL1 or PDL2 amplification were treated with PD-1/ PD-L1 inhibitors either alone or in combination with CTLA-4 or an investigational agent and had an objective response rate of 67% and a median progression-free survival of 15 months 97 . This small cohort illustrates the challenges of widespread applicability given the low prevalence of PDL1 CNAs, emphasizing that this finding is preliminary PD-L1 regulation. Since PD-L1 associates with response to checkpoint blockade 6, 7 , understanding PD-L1 regulation may reveal novel molecular mechanisms that could be targeted to overcome resistance to immune checkpoint inhibitors. Recent work has demonstrated that cyclin D-cyclin dependent kinase 4 (CDK4) and speckle-type POZ (pox virus and zinc finger) protein (SPOP) regulate PD-L1 protein abundance by promoting proteasome-mediated degradation of PD-L1 and that CDK4 and CDK6 (CDK4/6) inhibitors increased PD-L1 protein levels and enhanced response to PD-1 inhibitors in preclinical models of cancer 98 . In 97 primary human prostate cancers, 15 tumors with SPOP mutations had stronger PD-L1 staining and a lower number of TILs than tumors without SPOP mutations 98 . Additional PD-L1 regulators have been revealed by functional genomic screens in human cancer cell lines. Specifically, haploid genetic screens and CRISPR-Cas9 knockouts revealed that CMTM4 and CMTM6 (CMTM4/6), two closely related transmembrane proteins, reduced PD-L1 protein ubiquitination and enhanced T cell inhibition by PD-L1-expressing tumors 99 . Another similar CRISPR-Cas9 screen also identified CMTM6 as a regulator that prevents PD-L1 protein degradation and showed that CMTM6 depletion improved tumor-specific T cell activity in vitro and in vivo 100 . Together, these findings on PD-L1 regulators have important therapeutic implications in the enhancement of immune checkpoint blockade response. CDK4/6 inhibitors are already being investigated with PD-1/PD-L1 inhibitors in clinical trials, and CMTM4/6 first requires validation in human tumors.
dNA repair and mutational signatures
Mismatch repair deficiency and other DNA repair alterations. Genomic analyses have also shown that mutational processes that directly alter DNA damage response and repair pathways influence response to immune checkpoint blockade 101 . Mismatch repair (MMR) deficiency has emerged as a robust indicator of response to immune checkpoint blockade 37, 40 . Alterations in genes encoding MMR proteins, including MLH1, MSH2, MSH6, and PMS2, lead to uncorrected DNA replication errors and a large number of mutations, particularly small insertions and deletions in repetitive DNA sequences called microsatellites 61 . These genomic alterations often cause frameshift mutations that produce immunogenic neoantigens that are recognized and targeted by T cells 102, 103 . Phase II clinical trials of single-agent PD-1 blockade in patients with MMR deficient tumors have demonstrated impressive response rates of 40-70% with durable progression-free and overall survival 37, 40 . These results culminated in the first FDA approval of a cancer therapy based on a genomic biomarker regardless of tumor histology and site of origin. Notably, patients with primary resistance had similar tumor mutation burden as patients with responses, and responding patients had transient expansions of T cell clones specific for neoantigens that bound MHC proteins with > 100-fold higher affinity than wild-type peptides 37 , highlighting neoantigen immunogenicity rather than mutation burden as a potential driver of response to immune checkpoint blockade.
The success of MMR deficiency as a response predictor has raised the question of whether other DNA repair alterations are similarly associated with checkpoint blockade response. Tumors with inactivating mutations in POLE, encoding a DNA polymerase essential to nucleotide and base-excision repair, have demonstrated impressive responses to PD-1 inhibition in multiple case studies 39, [104] [105] [106] . Another study of PD-1/PD-L1 inhibitors in metastatic urothelial carcinoma showed higher response rates in tumors with DNA damage response alterations compared with those without these alterations, and the highest response rates were in tumors with lossof-function alterations as opposed to alterations of unknown significance 107 . Importantly, statistical models that included DNA damage response alterations were superior at predicting survival compared with models accounting for mutation load 107 , indicating that alterations in DNA damage response pathways may impact response to immune checkpoint inhibitors more than mutation load.
Mutational signatures.
Beyond dysfunctional DNA repair, specific mutational signatures, which are characteristic patterns of mutation types generated by different mutational processes, have been linked to checkpoint blockade response. Among patients with lung cancer treated with checkpoint inhibitors, tumors harboring mutational signatures associated with smoking had a higher response rate than those without such smoking signatures 39, 53 . Another cohort of patients with lung cancer who experienced durable clinical benefit from anti-PD-1 therapy displayed an enrichment of mutational signatures associated with apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), a family of RNA and DNA editing proteins capable of promoting mutagenesis in cancer 108 . Likewise, patients with bladder cancer and head and neck squamous cell carcinoma demonstrated a significant association between APOBEC-related mutational signatures and response to immune checkpoint inhibitors 53 . Finally, patients with melanoma who were treated with checkpoint blockade were more likely to experience clinical benefit if their tumors harbored mutational signatures associated with ultraviolet light exposure or prior alkylating agent treatment as opposed to other dominant mutational signatures, and stratification by mutational signature eliminated the association of mutation burden with response, suggesting that mutation burden may not be an underlying driver of response in melanoma 53 .
It will be of interest to understand whether these DNA-damaging
Oncogenic signaling pathways
Certain cancer signaling pathways may influence response to immune checkpoint blockade by promoting immune evasion. Increasing evidence points to intratumoral immune exclusion as a dominant strategy employed by oncogenic pathways to limit response to immune checkpoint inhibitors 109 . Tumor immune microenvironments containing cytotoxic lymphocytes surrounding but not infiltrating the tumor core are termed immune-excluded or cold tumors, while those microenvironments with activated cytotoxic lymphocytes infiltrating the tumor core are referred to as immune-infiltrated or hot tumors 110, 111 . In patients with metastatic melanoma, immune-excluded tumors demonstrated poorer responses to both CTLA-4 and PD-1 inhibitors than immune-infiltrated tumors 14, 112 . Here, we discuss alterations in oncogenes and tumor-suppressor genes that contribute to intratumoral immune exclusion and checkpoint blockade resistance.
Tumor suppressors and oncogenes. Lung adenocarcinomas with inactivation of the tumor suppressor gene serine/threonine-protein kinase (STK11, also known as LKB1) have been shown to have a reduced number of TILs and worse responses to immune checkpoint inhibitors in multiple studies 45, [113] [114] [115] . An emerging mechanism by which LKB1 alterations facilitate immune exclusion is methylation-induced suppression of stimulator of interferon genes (STING) expression that blocks cytoplasmic double-stranded DNA sensing, which otherwise induces type 1 interferons and T cell recruitment 116 . Furthermore, inactivation of LKB1 in a KRAS-driven genetically engineered mouse model of non-small-cell lung cancer was associated with increased interleukin-6 expression, enhanced recruitment of neutrophils, and decreased T cell infiltrate, phenomena that could be reversed with interleukin-6 blockade or neutrophil depletion 113 . Loss of PTEN, another tumor suppressor, was similarly associated with increased immunosuppressive cytokines, decreased T cell tumor infiltration, and inferior responses to PD-1 inhibitors in patients with melanoma and xenograft models of melanomas 117 , as well as in a patient with uterine leiomyosarcoma 118 . In addition, PTEN-deficient melanomas displayed reduced autophagy-related transcript and protein levels that led to resistance to T cell killing in vitro 117 . Importantly, autophagy has been reported to enhance tumor immunogenicity by recruiting dendritic cells, increasing cross-presentation and priming T cells 119, 120 , an essential step in anti-tumor immunity in which dendritic cells introduce T cells to neoantigens and trigger cytotoxic differentiation 121 . Whether defective T cell priming contributes to immune exclusion and PD-1 resistance in PTEN-deficient tumors remains to be studied 109 . Activating oncogenic alterations associated with intratumoral immune exclusion and checkpoint blockade resistance include WNT/β-catenin and transforming growth factor-β (TGF-β) 122, 123 . β-catenin signaling has been shown to prevent T cell tumor infiltration by decreasing dendritic cell recruitment and T cell priming in autochthonous mouse melanoma models 124, 125 . Conversely, multiple lines of evidence suggest that TGF-β signaling in fibroblasts creates a stromal barrier to physically exclude T cells from the tumor core in patients who did not respond to immune checkpoint inhibitors 123, 126 . Hence, strategies to enhance checkpoint blockade response need to be tailored to the specific immune exclusion mechanisms employed by each oncogenic pathway.
Clonal driver alterations.
Certain clonal driver alterations also correlate with immune exclusion and checkpoint blockade response. Murine models of EGFR-mutated lung tumors showed higher levels of immunosuppressive growth factors and a lower ratio of cytotoxic (CD8 + ) to regulatory (Foxp3 + ) tumor-infiltrating T cells compared to normal lung 127 , and both human and murine EGFR-mutated lung tumors displayed lower numbers of infiltrating CD8
+ T cells compared with KRAS-mutated lung tumors 128 . Notably, patients with EGFR-mutated non-small-cell lung cancer have demonstrated a low response rate to anti-PD-1/PD-L1 therapy 45, 129 . Moreover, a large meta-analysis of patients with lung cancer who were randomized to anti-PD-1/PD-L1 therapy or chemotherapy found no overall survival benefit of checkpoint blockade in 271 patients with EGFR-mutation-positive lung cancers and a statistically significant treatment-EGFR mutation interaction in the overall cohort of more than 2,000 patients with known EGFR status 130 , suggesting that EGFR mutations are indeed a robust predictor of PD-1 blockade resistance.
Conversely, the relationship of KRAS with checkpoint blockade response is more variable. In the same meta-analysis, patients with KRAS-mutation-positive tumors had improved overall survival with anti-PD-1/PD-L1 therapy as compared to chemotherapy, but the interaction between mutation status and treatment effect was not significant for KRAS mutations 130 . Likewise, another smaller study found no enrichment of KRAS in lung cancers responding to PD-1/PD-L1 inhibitors 45 , and many studies have implicated KRAS in chemokine upregulation and immunosuppressive cell recruitment 131, 132 . Therefore, the association of KRAS mutations with checkpoint inhibitor response likely depends on additional factors, such as tissue context and coexisting mutations. Specifically, KRASmutated pancreatic tumors have fewer infiltrating T cells than KRAS-mutated lung tumors 132 , and KRAS-mutated lung tumors with TP53 mutations have better responses to PD-1 inhibitors 133 , particularly when compared with KRAS-mutated lung tumors with LKB1 mutations 114 . Ultimately, the impact of tissue stroma and concurrent mutations on the immunologic effects of clonal driver mutations requires further clarification and must be considered in future biomarker-development efforts.
Transcriptional signatures and the tumor microenvironment
Transcriptional signatures linked to immune checkpoint inhibitor response encompass the broader tumor immune microenvironment and expose underlying pathways of response and resistance. These signatures have been derived from bulk RNA and thus represent an amalgamation of tumor cells, immune cells, and stromal cells. Gene expression analyses of clinical tumor samples have found that checkpoint blockade response correlates with T cell infiltration, cytotoxic function, antigen processing, checkpoint molecules, and decreased suppressor cells 85, [134] [135] [136] [137] , including immune checkpoint relationships derived from spontaneously regressing neuroblastoma tumors 138 . One important caveat is that all of the signatures presented here require confirmation by independent groups and prospective clinical validation.
Immune infiltration and stromal signaling. From a functional standpoint, higher T effector and IFN-γ response gene expression, including of CD8A, EOMES, GZMA and GZMB, and IFNG, was strongly associated, in randomized phase II studies, with improved overall survival in patients with non-small-cell lung cancer treated with a PD-L1 inhibitor 134 and improved progression-free survival in patients with metastatic renal cell carcinoma treated with a PD-L1 inhibitor with or without anti-vascular endothelial growth factor (VEGF) therapy 52 . More than likely, this gene signature points to the existing presence of an effector T cell response, poised to respond to anti-PD-1 therapy. Another immune infiltration transcriptional signature is a T-cell-inflamed gene expression profile that comprises 18 genes involved in antigen presentation, chemokine production, cytolytic activity, and T cell exhaustion 85, 139 . This signature has been shown to predict clinical response to anti-PD-1 inhibition in over 300 patients across 22 tumor types 115 . Transcriptional signatures associated with resistance to checkpoint immunotherapy have focused on stromal and vascular biology. The innate anti-PD-1 resistance signature (IPRES), derived from bulk RNA sequencing of tumor biopsies, was associated with primary resistance to PD-1 blockade in patients with melanoma and included enhanced expression of genes involved in stromal and vascular pathways, such as mesenchymal transition, cell adhesion, extracellular matrix remodeling, angiogenesis, and wound healing 140 . Similarly, resistance to anti-PD-1 inhibition in over 300 patients across 22 tumor types correlated with enriched expression of genes related to vascular endothelium, myeloid infiltrates, and stromal Wnt signaling 115 . These studies highlight the contribution of stromal and endothelial components of the tumor microenvironment to checkpoint blockade resistance, which requires further clarification in future work.
T cell dysfunction and exclusion. Another transcriptional signature predictive of checkpoint blockade response integrated both T cell exclusion in cold tumors and T cell dysfunction in hot tumors in a computational framework termed tumor immune dysfunction and exclusion (TIDE) using gene expression and survival data from over 33,000 human tumor samples 141 . Whereas the TIDE T cell exclusion signature was derived from expression profiles of immunosuppressive cells, including cancer-associated fibroblasts, myeloid-derived suppressor cells, and tumor-associated macrophages, the TIDE T cell dysfunction signature employed Cox proportional hazards models to identify genes that interact with cytotoxic T lymphocyte function to influence survival, producing a signature enriched for immune inflammatory pathways and depleted of T cell activation pathways 141 . The combined overall TIDE signature predicted checkpoint immunotherapy response better than tumor mutation load and uncovered SERPINB9, a gene encoding a protein inactivator of granzyme B and normally expressed in immune cells and immune-privileged sites, as a novel mechanism underlying immune evasion in cancer cells 141 . Identifying additional mechanisms of resistance in immune-infiltrated tumors that have high levels of IFN-γ will facilitate preclinical investigation of combination agents aimed at overcoming acquired resistance to checkpoint blockade.
Unlike bulk RNA sequencing, single-cell RNA sequencing allows the detection of resistance mechanisms specific to tumor subpopulations, such as cancer cells, immune cells, and fibroblasts. One such single-cell RNA sequencing study in melanoma revealed a transcriptional signature in malignant cells associated with T cell exclusion and checkpoint immunotherapy resistance that consisted of reduced antigen presentation, IFN-γ signaling, complement response, and immune modulation pathways, as well as enriched expression of chromatin regulators, transcription factors, and cyclin-dependent kinases or targets, particularly CDK4 and CDK7 (ref. 
T cell functionality and heterogeneity
T cell clonality. Efforts to define a functional T cell response to checkpoint blockade using genomic approaches initially focused on the clonality of the T cell response using T cell population RNA sequencing approaches. Assessments of T cell clonality traditionally relied on sequencing the β chain of the hypervariable complementarity-determining region 3 (CDR3) of the TCR to identify a unique T cell clone because the extreme polymorphism of this region is thought to be the primary determinant of antigen-recognition specificity 143 . Greater T cell clonality, ranging from 0 to 1, with 1 indicating a monoclonal population, suggests a more restricted T cell response to a small number of antigens, such as those within the tumor microenvironment. Increased T cell clonality has been correlated with improved response to PD-1 blockade in melanoma, with a higher abundance of pre-treatment clones identified after PD-1 blockade 14, 144 . Although there was no difference in clonality among responders and non-responders to anti-CTLA-4 therapy, those patients who had received anti-CTLA-4 blockade before PD-1 therapy showed an increase in T cell clonality 144 .
In comparison, patients with non-small-cell lung cancer with acquired resistance to PD-1 blockade with or without CTLA-4 inhibition demonstrated diminished TCR clonality 41 . This decrease in clonal TCR frequency contrastsd with the clonal TCR expansion seen during initial response 41 . While this work highlights the overall diversity of the T cell response as a potential critical factor for checkpoint inhibitor response, this approach cannot match the TCR to its cognate neo-epitope. Instead, advances in single-cell RNA sequencing that identify the full-length TCR-α and TCR-β chains 145 , when combined with improved algorithms for prediction of neoantigens, may provide more definitive evidence about the relationship between T cell clonality and corresponding neoantigens in response to checkpoint blockade.
T cell exhaustion and stemness. Based on work in mouse models of chronic viral infections, a nuanced view of T cell functionality has emerged with the recognition that the 'exhausted' CD8
+ PD-1 + T cell population itself is heterogenous, and a subset of the T cells respond to PD-1 blockade 146, 147 . These populations may be more broadly broken into two classes: a subset that is considered to be 'progenitors' or 'stem-cell-like' , which expresses the chemokine receptor CXCR5
+ and the transcription factor TCF7 (also known as TCF1), lacks the co-inhibitory receptor TIM-3, and is capable of responding to checkpoint blockade and giving rise to effector T cell progeny; and a 'terminally exhausted' subset that lacks CXCR5 or TCF7 but expresses TIM-3 and does not proliferate in response to PD-1/PD-L1 blockade 147, 148 . The stem-like population of CD8
+ PD-1 + CXCR5 + TIM-3 -T cells has been identified in lung cancer tumors via multiparameter flow cytometry and is similar to a subset of CD8 + T cells in melanoma identified by single-cell RNA sequencing approaches 149 . More recently, this CD8 + TCF7 + T cell population, also expressing the IL-7 receptor, has been found to be enriched in melanoma tumors that respond to checkpoint blockade, which was confirmed in an independent cohort 150 . A CD8 + T cell population expressing TIM-3 and CD39, an ectonucleotidase involved in adenosine signaling, was enriched in non-responders 150 . While this work focused on the CD8 + T cell compartment, additional analyses of single-cell data will likely further illuminate the role that heterogeneity plays in other T cell subsets, including regulatory T cells, CD4
+ helper and effector cells, and tissue-resident T cells, as well as the myeloid cell compartment, and the contributions of these immune cell subtypes to responsiveness to immunotherapy.
chromatin modifier genes
SWI-SNF chromatin remodeling complexes regulate genomic architecture 151 and impact response to checkpoint inhibitors. Inactivating mutations in the PBRM1 gene, which encodes a subunit of the PBAF SWI-SNF chromatin remodeling complex, conferred susceptibility to dual PD-1 and CTLA-4 inhibition in mouse melanoma tumors otherwise resistant to checkpoint blockade, and PBRM1-deficient cells showed enhanced chromatin accessibility and significantly enriched expression of IFN-γ response genes, including genes encoding chemokines that recruit effector T cells, resulting in increased intratumoral cytotoxic CD8 . PBRM1 loss additionally correlated with checkpoint inhibitor response in patients with metastatic renal cell carcinoma 154 . Notably, the benefit conferred by PBRM1 loss was predominantly observed in patients who had been previously treated, the majority of whom received VEGF inhibitors, and not in patients receiving anti-PD-1/PD-L1 as first-line treatment 154 . Prior analyses of patients with metastatic renal cell carcinoma demonstrated that PBRM1 mutations correlated with improved response to first-line VEGF inhibitors 155, 156 . A subsequent randomized phase II study of patients with treatment-naive metastatic renal cell carcinoma also found that PBRM1 mutations were associated with improved responses in patients for whom first-line treatment was a VEGF inhibitor, but not in patients for whom it was a PD-L1 inhibitor with or without a monoclonal anti-VEGF antibody 52 . Altogether, these works indicate that prior anti-angiogenic therapy influences the association between PBRM1 status and response to anti-PD-1/PD-L1 therapy, underscoring the need for further investigation of this pathway and the conclusion that PBRM1 mutations should not presently be advanced as a clinical biomarker.
AT-rich interactive domain-containing protein 1A (ARID1A) and SWI-SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4 (SMARCA4), two other genes encoding SWI-SNF chromatin remodeling complex subunits, have similarly been linked to response to checkpoint inhibitors. In mice with ARID1A-deficient ovarian tumors, PD-L1 inhibition led to reduced tumor burden and prolonged survival compared with controls 157 . This study found that ARID1A loss and impaired ARID1A binding to the MMR protein MSH2 similarly reduced MMR and increased mutation frequency, leading the authors to hypothesize that ARID1A loss may increase response to checkpoint blockade through MMR deficiency 157 . Another study reported that four patients with ovarian small-cell carcinoma, a low-mutation cancer driven by loss-of-function SMARCA4 mutations, had impressive responses to anti-PD-1 therapy 158 . Taken together, these studies demonstrate a role for chromatin-modifier genes in response to checkpoint inhibitors and highlight the need to confirm these findings and investigate the relationship between other epigenetic changes and checkpoint blockade response.
Additional recurrent genetic alterations
Other recurrent genetic alterations have been linked to response to immune checkpoint blockade, including SERPINB3 and SERPINB4 (SERPINB3/4), genes encoding serine protease inhibitors involved in apoptosis and autoimmunity 159 , and CNAs. In two independent melanoma cohorts, it was found that SERPINB3/4 mutations were associated with clinical benefit and longer survival after anti-CTLA-4 therapy 159 . Inactivating mutations in SERPINB3/4 cause proteins to misfold and form inflammatory aggregates capable of triggering autoimmune disease, leading to the hypothesis that SERPINB3/4 mutations initiate a broad tumor immune response reactivated by checkpoint inhibitors 159 . In contrast, CNAs have been connected to resistance to checkpoint blockade. A high number of somatic CNAs in patients with melanoma treated with anti-CTLA-4 therapy correlated with worse survival, and over 5,000 tumors of 12 cancer types with high levels of whole-chromosome and chromosome-arm CNAs exhibited reduced expression of cytolytic immune cell genes, specifically CD247, CD2, CD3E, GZMH, NKG7, PRF1, and GZMK
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. Similarly, an analysis of patients with melanoma treated with checkpoint inhibitors found that non-responding tumors had a higher burden of copy-number loss and reduced expression of immune-related genes, including cytolytic markers, HLA molecules, IFN-γ pathway genes, chemokines, and adhesion molecules 144 . In sum, these studies indicate that tumor aneuploidy may be associated with decreased tumor immune infiltrates and resistance to checkpoint blockade, suggesting that CNAs may represent a survival strategy for tumors, allowing them to escape strong anti-tumor immune responses. The mechanism underlying this association may be related to lost immunogenic neoantigens enhancing immune evasion or another pathway that has yet to be discovered.
Toward clinical translation
The aforementioned genomic correlates of immune checkpoint response may serve as a blueprint around which to develop targeted therapies to overcome immune checkpoint inhibitor resistance. This section presents examples of potential therapeutic applications sparked by these genomic observations (Table 2) . Numerous combination regimens with immune checkpoint blockade exist beyond those related to genomic alterations and are reviewed comprehensively elsewhere 23, 161, 162 .
Neoantigen vaccines. One of the most advanced areas in immunogenomics therapeutic development is personalized cancer vaccines. These efforts utilize next-generation-sequencing-based analyses to identify and target predicted neoantigens with patientspecific vaccines that stimulate an immune response tailored to each individual's tumor mutational profile 163 . Two recent studies have demonstrated that personalized neoantigen vaccines based on individual tumor whole-exome and transcriptome sequencing augmented existing T cell responses and activated new T cell responses in patients with advanced or newly metastatic melanoma 164, 165 . In addition, three patients with radiologically detected metastatic lesions at the start of neoantigen vaccination, who subsequently progressed, experienced complete responses with the addition of anti-PD-1 therapy 164, 165 . These neoantigen vaccines are currently being examined in multiple clinical trials in other cancers with lower neoantigen burden, including renal cell carcinoma (NCT02950766), glioblastoma (NCT03422094), follicular lymphoma (NCT03361852), and chronic lymphocytic leukemia (NCT03219450) with and without immune checkpoint inhibitors. Whether the enhanced T cell priming and activation effects of neoantigen vaccines can overcome checkpoint blockade resistance has yet to be established.
Interferon therapies. Another approach to addressing checkpoint blockade resistance focuses on therapies that boost anti-tumor immunity through IFN activation. IFN-γ-responsive genes involved in antigen presentation, cytokine signaling, cytotoxic activity, and adaptive immunity have been shown to correlate with response to checkpoint inhibitors 85, 115 . Phase I/II trials investigating combinations of IFN-γ and checkpoint inhibitors are underway in advanced solid tumors and refractory lymphomas (NCT02614456, NCT03063632). The IFN-γ receptor depends on the JAK-STAT signal transduction pathway to regulate transcription of IFN-γ-inducible genes 166 , so JAK inhibitors may curtail the efficacy of checkpoint inhibitors. In support of this concept, a phase I clinical trial in advanced solid tumors showed that the JAK1 inhibitor itacitinib combined with the PD-1 inhibitor pembrolizumab reduced peripheral T cell activation and did not affect intratumoral CD8 + T cell or T regulatory cell levels, leading to lower-thanexpected response rates 167 . Alternatively, T cell priming may depend on IFN-β activation by the STING protein complex acting as an endoplasmic reticulum receptor that propagates cytosolic double-stranded DNA sensing to trigger an anti-tumor immune response 113, 168 . Although many STING agonists are under clinical development in combination with checkpoint inhibitors (NCT02675439, NCT03172936, NCT03010176), the single-agent activity of these therapies has been limited 169, 170 . , embodies an emerging tactic to transform immune-excluded tumors into immune-infiltrated tumors. In mouse models of cancer, human breast cancer cell lines, and clinical breast cancer biopsies, CDK4/6 inhibitors have been shown to promote anti-tumor immunity by reducing regulatory T cell proliferation, enhancing effector T cell activation, and improving antigen presentation through decreased methylation of endogenous retroviruses [171] [172] [173] . Moreover, mouse models of colon, lung, and breast cancer have shown that CDK4/6 inhibitors augment responses to PD-1 blockade [171] [172] [173] , and preliminary clinical data suggest that CDK4/6 inhibition improves responses to PD-1 blockade in hormone-receptor-positive metastatic breast cancer as compared with . Numerous phase I/II trials combining CDK4/6 inhibitors with checkpoint immunotherapy are ongoing across tumor types, including breast, ovarian, lung, and head and neck cancers (NCT03147287, NCT03294694, NCT02779751, NCT03498378).
Anti-TGF-β therapies. Finally, TGF-β signaling in fibroblasts constitutes another critical mechanism of immune exclusion and resistance to checkpoint inhibitors 126 , as demonstrated by the finding that combined blockade of TGF-β and PD-L1 reduced stromal TGF-β signaling and augmented T cell tumor infiltration and tumor regression in a mouse model of immune-excluded mammary carcinoma 123 . Likewise, in mouse models of colorectal adenocarcinomas, TGF-β inhibition conferred susceptibility to anti-PD-L1 therapy with augmented infiltrating lymphocytes and type 1 T helper cell activation that led to metastasis eradication 175 . On the basis of this evidence, combined TGF-β and PD-1/PD-L1 inhibition is under evaluation in phase I/II trials in advanced solid tumors (NCT02947165, NCT02734160, NCT02423343). Moreover, the bifunctional fusion protein M7824, consisting of a PD-L1 monoclonal antibody linked to TGF-β receptor II, which traps all three TGF-β isoforms, displayed more effective tumor suppression than single-agent therapy in syngeneic mouse models, including longterm survival and anti-tumor immunity 176 . The dose-escalation component of a phase I study (NCT02517398) investigating this agent demonstrated a manageable safety profile and some durable responses 177 , although whether this agent is more effective than PD-L1 inhibition alone has yet to be established. Table 2 displays ongoing clinical trials of therapeutic mechanisms targeting these genomic correlates of response to improve efficacy of immune checkpoint inhibitors.
Clinical trial innovation. Innovation in trial design, patient recruitment, and clinical endpoints will help determine the best therapies informed by genomic data to combine with checkpoint blockade to overcome resistance. Basket trials organized around a specific molecular alteration constitute an important strategy to test immunotherapy combinations across tumor types in biomarker-selected patients with the highest probability of benefit (Fig. 3a) 
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. Adaptive trials may similarly augment enrollment into subgroups with promising response rates by using interim analyses to make sample size modifications that ensure statistical power in the subgroup of interest (Fig. 3b) 
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. Novel trial designs for combination dose-escalation studies include run-in periods that allow sequential combination after monotherapy within the same patient, zig-zag schedules that alternate agents for dose increases, and bifurcated arms with monotherapy escalation and combination escalation at a lower dose 180 . Beyond trial designs, patient recruitment can be improved with automated tools that prompt clinicians to consider patient-specific trials matched to actionable genomic alterations at key clinical and research time points, including when scans or labs indicate progressive disease, when tumor genetic testing is completed, and when new trials open 178 . To address the nonlinear dose-response and dose-toxicity kinetics of checkpoint inhibitors, early-phase trials should explore novel biomarker-driven response criteria and surrogate endpoints, such as circulating tumor DNA and target receptor occupancy, while avoiding additive dosing without efficacy benefits 181, 182 . Likewise, new endpoints for later-stage studies, such as immune-related response criteria and durable response rate, require continued investigation 180 . Most importantly, in light of the rapidly ballooning quantity of immuno-oncology trials, academic institutions and pharmaceutical companies need to coordinate trial efforts and sharing of correlative science data to prevent redundancy and prioritize the most promising checkpoint inhibitor combinations 161 .
Future directions
Much work remains to develop these correlates of checkpoint blockade response into reliable biomarkers that can guide treatment decisions and therapeutic development. First and foremost, many of these concepts need to be validated in functional preclinical models and prospective clinical cohorts. Moreover, the search for additional genomic correlates requires clinically annotated patient cohorts with sample sizes into the hundreds and even thousands to detect rare response-associated variants 53 . This effort necessitates populations with greater diversity of race, ethnicity, age, and tumor histology 183 . Future discovery efforts should focus on detailed genomic and clinical characterization coupled with thorough investigation of less explored areas, including epigenomics, proteomics, and metabolomics, to fully characterize the relationship of host immunity, tumor biology, and the microbiome to checkpoint inhibitor response. Comprehensive clinical databases of patients treated with checkpoint inhibitors must be effectively integrated with preclinical models and screens. Ultimately, systems biology and bioinformatic approaches are needed to coordinate this vast array of information, to assess the relative importance of each component, and to develop risk scores to capture the complexity of multiple driving alterations influencing response. Altogether, these efforts to contextualize genomic correlates into the larger tumor-immune biology will build a deeper quantitative and conceptual understanding of response and resistance to checkpoint blockade to better promote the development of rational biomarkers and therapies. Review ARticle | FOCUS
